Hamburg Edoxaban for Anticoagulation in COVID-19 Study
Latest Information Update: 25 May 2023
At a glance
- Drugs Edoxaban (Primary) ; Fondaparinux sodium; Low molecular weight heparins
- Indications Arterial thrombosis; COVID 2019 infections; Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms HERO-19
- 21 May 2023 Status changed from discontinued to completed.
- 27 Jan 2023 Status changed from recruiting to discontinued.
- 16 May 2022 Planned End Date changed from 1 Sep 2022 to 1 Mar 2023.